-
-
-
-
-
-
-
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
-
-
-
-
-
-
-
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
-
-
-
-
-
-
-
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
-
-
-
-
-
-
-
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
-
-
-
-
-
-
-
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
-
-
-
-
-
-
-
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
-
1,160,184 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

